Replimune Group, Inc. Earnings Per Share Disclosure
| Year ended March 31, | |||||||||||
| 2025 | 2024 | ||||||||||
| Numerator: | |||||||||||
| Net loss | $ | (247,297) | $ | (215,794) | |||||||
| Denominator: | |||||||||||
| Weighted average common shares outstanding, basic and diluted | 80,564,147 | 66,569,894 | |||||||||
| Net loss per share, basic and diluted | $ | (3.07) | $ | (3.24) | |||||||
| Year ended March 31, | |||||||||||
| 2025 | 2024 | ||||||||||
| Options to purchase common stock | 10,214,878 | 8,652,256 | |||||||||
Unvested restricted and performance stock units | 3,611,774 | 2,397,890 | |||||||||
| Warrants to purchase common stock | 497,344 | 497,344 | |||||||||
| 14,323,996 | 11,547,490 | ||||||||||
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.